Mylan (MYL) Sued by Shareholder Over EpiPen Payments
- Record-setting rally pushes on as S&P ends week up 3 percent
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Mylan (NASDAQ: MYL) shares are on watch after an investor sued the company over allegations that it made misstatements on payments made to government health-insurance programs with respect to its EpiPen product, according to Bloomberg.
The lawsuit was filed in Manhattan court Tuesday.
Shares of Mylan are down around 1 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mylan (MYL) Announces Restructuring Program; Sees Workforce Impact
- Whirlpool (WHR) Says U.S. Government Confirms Samsung and LG Dumped Washers in US - DJ
- Flowers Foods (FLO) and Flowers Baking Reach Settlement in Class Action Lawsuit